1039743-19-5Relevant academic research and scientific papers
Design of potent and selective GPR119 agonists for type II diabetes
Szewczyk, Jason W.,Acton, John,Adams, Alan D.,Chicchi, Gary,Freeman, Stanley,Howard, Andrew D.,Huang, Yong,Li, Cai,Meinke, Peter T.,Mosely, Ralph,Murphy, Elizabeth,Samuel, Rachel,Santini, Conrad,Yang, Meng,Zhang, Yong,Zhao, Kake,Wood, Harold B.
, p. 2665 - 2669 (2011/06/20)
Screening of the Merck sample collection identified compound 1 as a weakly potent GPR119 agonist (hEC50 = 3600 nM). Dual termini optimization of 1 led to compound 36 having improved potency, selectivity, and formulation profile, however, modest
